Risk-Adapted Treatment of Ph- Myeloproliferative Neoplasms

Sandra E. Kurtin, PhDc, ANP-C, AOCN®
Arizona Cancer Center

Posted: 7/16/2018
Expires: 7/16/2019
Estimated time to complete: 1 hour

This activity is supported by educational grants provided by Amgen, AstraZeneca, Celgene Corporation, Incyte Corporation, Merck Sharp & Dohme Corp., Takeda Oncology, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Instructions for Earning CE credit

This activity has expired, credit is no longer available.


Quick Tips

What are the germline mutations in patients predisposed to MPN/MDS?
What should I know about the JAK-STAT biochemical signaling pathway?
What are the latest WHO disease definitions for diagnosing myeloproliferative neoplasms?
Copyright © 2010-2021 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.